{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:14:07Z","timestamp":1782846847891,"version":"3.54.5"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["82DZL004A1 82DZL009B1"],"award-info":[{"award-number":["82DZL004A1 82DZL009B1"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Chronic rhinosinusitis (CRS) usually presents with nasal congestion, rhinorrhea and anosmia impacts quality of life in cystic fibrosis (CF). Especially mucopyoceles pathognomonic for CRS in CF may cause complications such as spread of infection. Previous studies using magnetic resonance imaging (MRI) demonstrated early onset and progression of CRS from infancy to school age in patients with CF, and mid-term improvements of CRS in preschool and school-age children with CF treated with lumacaftor\/ivacaftor for at least 2\u00a0months. However, long-term data on treatment effects on paranasal sinus abnomalities in preschool and school-age children with CF are lacking.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> 39 children with CF homozygous for F508del (mean age at baseline MRI 5.9 \u00b1 3.0\u00a0years, range 1-12\u00a0years) underwent MRI before (MRI1) and about 7\u00a0months after starting lumacaftor\/ivacaftor and then annually (median 3 follow-up MRI, range 1\u20134) (MRI2-4). MRI were evaluated using the previously evaluated CRS-MRI score with excellent inter-reader agreement. For intraindividual analysis ANOVA mixed-effects analysis including Geisser-Greenhouse correction and Fisher\u2019s exact test, and for interindividual group analysis Mann-Whitney test were used.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The CRS-MRI sum score at baseline was similar in children starting lumacaftor\/ivacaftor in school age and children starting therapy at preschool age (34.6 \u00b1 5.2 vs.32.9 \u00b1 7.8, <jats:italic>p<\/jats:italic> = 0.847). Mucopyoceles were the dominant abnormality in both, especially in maxillary sinus (65% and 55%, respectively). In children starting therapy in school age the CRS-MRI sum score decreased longitudinally from MRI1 to MRI2 (\u22122.1 \u00b1 3.5, <jats:italic>p<\/jats:italic> &amp;lt; 0.05), MRI3 (\u22123.0 \u00b1 3.7, <jats:italic>p<\/jats:italic> &amp;lt; 0.01) and MRI4 (\u22123.6 \u00b1 4.7, <jats:italic>p<\/jats:italic> &amp;lt; 0.01), mainly due to a decrease in the mucopyoceles subscore (\u22121.0 \u00b1 1.5, <jats:italic>p<\/jats:italic> = 0.059; \u22121.2 \u00b1 2.0, <jats:italic>p<\/jats:italic> &amp;lt; 0.05; \u22121.6 \u00b1 1.8, <jats:italic>p<\/jats:italic> &amp;lt; 0.01; and \u22122.6 \u00b1 2.8, <jats:italic>p<\/jats:italic> = 0.417, respectively). In children starting lumacaftor\/ivacaftor in preschool age, the CRS-MRI sum score remained stable under therapy over all three follow-up MRI (0.6 \u00b1 3.3, <jats:italic>p<\/jats:italic> = 0.520; 2.4 \u00b1 7.6, <jats:italic>p<\/jats:italic> = 0.994; 2.1 \u00b1 10.5, <jats:italic>p<\/jats:italic> &amp;gt; 0.999 and \u22120.5 \u00b1 0.5, <jats:italic>p<\/jats:italic> = 0.740; respectively).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Longitudinal paranasal sinus MRI shows improvements in paranasal sinus abnormalities in children with CF starting lumacaftor\/ivacaftor therapy at school age. Further, MRI detects a prevention of an increase in paranasal sinus abnormalities in children with CF starting lumacaftor\/ivacaftor therapy at preschool age. Our data support the role of MRI for comprehensive non-invasive therapy and disease monitoring of paranasal sinus abnormalities in children with CF.<\/jats:p>","DOI":"10.3389\/fphar.2023.1161891","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T04:21:40Z","timestamp":1681100500000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Long-term effects of lumacaftor\/ivacaftor on paranasal sinus abnormalities in children with cystic fibrosis detected with magnetic resonance imaging"],"prefix":"10.3389","volume":"14","author":[{"given":"Lena","family":"Wucherpfennig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Wuennemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Eichinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon Y.","family":"Graeber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengkai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaehi","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens-Peter","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulsattar","family":"Alrajab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Ulrich","family":"Kauczor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus A.","family":"Mall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Sommerburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark O.","family":"Wielp\u00fctz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jcf.2013.01.002","article-title":"Importance of bacteriology in upper airways of patients with Cystic Fibrosis","volume":"12","author":"Berkhout","year":"2013","journal-title":"J. Cyst. Fibros."},{"key":"B2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1513\/AnnalsATS.202101-057OC","article-title":"Impact of cystic fibrosis transmembrane conductance regulator therapy on chronic rhinosinusitis and health status: Deep learning CT analysis and patient-reported outcomes","volume":"19","author":"Beswick","year":"2022","journal-title":"Ann. Am. Thorac. Soc."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-023-07859-4","article-title":"Effects of CFTR-modulator triple therapy on sinunasal symptoms in children and adults with cystic fibrosis","author":"Bode","year":"2023","journal-title":"Eur. Arch. Otorhinolaryngol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e0116029","DOI":"10.1371\/journal.pone.0116029","article-title":"Comparison of microbiomes from different niches of upper and lower airways in children and adolescents with cystic fibrosis","volume":"10","author":"Boutin","year":"2015","journal-title":"PLoS One"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3390\/antiox10091412","article-title":"Increased inflammatory markers detected in nasal lavage correlate with paranasal sinus abnormalities at MRI in adolescent patients with cystic fibrosis","volume":"10","author":"Chung","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"De Boeck","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jcf.2020.07.002","article-title":"Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis","volume":"20","author":"DiMango","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"B8","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1080\/028418501127347214","article-title":"CT characterization of developmental variations of the paranasal sinuses in cystic fibrosis","volume":"42","author":"Eggesbo","year":"2001","journal-title":"Acta Radiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1513\/AnnalsATS.202008-1054OC","article-title":"Effects of Lumacaftor-Ivacaftor on Lung Clearance Index, Magnetic Resonance Imaging, and Airway Microbiome in Phe508del Homozygous Patients with Cystic Fibrosis","volume":"18","author":"Graeber","year":"2021","journal-title":"Ann. Am. Thorac. Soc."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1164\/rccm.201710-1983OC","article-title":"Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis","volume":"197","author":"Graeber","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of Elexacaftor\/Tezacaftor\/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles","volume":"205","author":"Graeber","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1053\/j.gastro.2004.07.006","article-title":"CFTR Cl-channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis","volume":"127","author":"Hirtz","year":"2004","journal-title":"Gastroenterology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S2213-2600(21)00069-2","article-title":"Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: A multicentre, phase 3, open-label, extension study","volume":"9","author":"Hoppe","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2500\/105065897781446676","article-title":"Paranasal sinus development in chronic sinusitis, cystic fibrosis, and normal comparison population: A computerized tomography correlation study","volume":"11","author":"Kim","year":"1997","journal-title":"Am. J. Rhinol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"642180","DOI":"10.3389\/fimmu.2021.642180","article-title":"Ivacaftor reduces inflammatory mediators in upper airway lining fluid from cystic fibrosis patients with a G551D mutation: Serial non-invasive home-based collection of upper airway lining fluid","volume":"12","author":"Mainz","year":"2021","journal-title":"Front. Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1136\/thx.2008.104711","article-title":"Concordant genotype of upper and lower airways P aeruginosa and S aureus isolates in cystic fibrosis","volume":"64","author":"Mainz","year":"2009","journal-title":"Thorax"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1164\/rccm.201910-1943SO","article-title":"Cystic fibrosis: Emergence of highly effective targeted therapeutics and potential clinical implications","volume":"201","author":"Mall","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1164\/rccm.202108-1986oc","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: A clinical trial","volume":"205","author":"Nichols","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jcf.2015.07.003","article-title":"Optical coherence tomography detects structural abnormalities of the nasal mucosa in patients with cystic fibrosis","volume":"15","author":"Oltmanns","year":"2016","journal-title":"J. Cyst. Fibros."},{"key":"B22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jcf.2011.09.009","article-title":"CT of the paranasal sinuses is not a valid indicator for sinus surgery in CF patients","volume":"11","author":"Rasmussen","year":"2012","journal-title":"J. Cyst. Fibros."},{"key":"B23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/00005537-200302000-00002","article-title":"Paranasal sinus development: A radiographic study","volume":"113","author":"Shah","year":"2003","journal-title":"Laryngoscope"},{"key":"B24","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1513\/AnnalsATS.201910-777OC","article-title":"Magnetic resonance imaging detects chronic rhinosinusitis in infants and preschool children with cystic fibrosis","volume":"17","author":"Sommerburg","year":"2020","journal-title":"Ann. Am. Thorac. Soc."},{"key":"B25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0165-5876(96)01458-9","article-title":"The paranasal sinuses in CT-imaging: Development from birth to age 25","volume":"39","author":"Spaeth","year":"1997","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1164\/rccm.201604-0893OC","article-title":"Comparison of lung clearance index and magnetic resonance imaging for assessment of lung disease in children with cystic fibrosis","volume":"195","author":"Stahl","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1164\/rccm.201807-1203OC","article-title":"Preventive inhalation of hypertonic saline in infants with cystic fibrosis (presis). A randomized, double-blind, controlled study","volume":"199","author":"Stahl","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jcf.2022.03.002","article-title":"Elexacaftor-Tezacaftor- Ivacaftor improves sinonasal outcomes in cystic fibrosis","volume":"21","author":"Stapleton","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B29","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/0091-6749(92)90184-4","article-title":"Complications of sinusitis","volume":"90","author":"Wagenmann","year":"1992","journal-title":"J. Allergy Clin. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1164\/rccm.201309-1659OC","article-title":"Magnetic resonance imaging detects changes in structure and perfusion, and response to therapy in early cystic fibrosis lung disease","volume":"189","author":"Wielp\u00fctz","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jcf.2022.03.011","article-title":"Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor\/tezacaftor\/ivacaftor therapy in adults with cystic fibrosis","volume":"21","author":"Wucherpfennig","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202209-763OC","article-title":"Longitudinal MRI detects onset and progression of chronic rhinosinusitis from infancy to school age in cystic fibrosis","author":"Wucherpfennig","year":"2022","journal-title":"Ann. Am. Thorac. Soc"},{"key":"B34","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1177\/0194599817717674","article-title":"Endoscopic management of paranasal sinus mucoceles: Meta-analysis of visual outcomes","volume":"157","author":"Zukin","year":"2017","journal-title":"Otolaryngol. Head. Neck Surg."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1161891\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T04:21:44Z","timestamp":1681100504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1161891\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,10]]},"references-count":34,"alternative-id":["10.3389\/fphar.2023.1161891"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1161891","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,10]]},"article-number":"1161891"}}